Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatm
July 09 2009 - 7:45AM
PR Newswire (US)
Findings Further Support Leptin as Part of Company's Integrated
Neurohormonal Therapy for Obesity (INTO) Strategy SAN DIEGO, July 9
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN) today announced positive results from a 28-week
dose-ranging study of pramlintide/metreleptin, a combination
treatment comprising pramlintide, an analog of the natural hormone
amylin, and metreleptin, an analog of the natural hormone leptin,
in overweight and obese patients. This Phase 2 study successfully
characterized patients who responded best to treatment and also
provided important information to inform dose selection. At 28
weeks, evaluable patients with a starting body mass index (BMI)
less than 35 kg/m2 (n=149), and treated with the highest
pramlintide/metreleptin doses, experienced significantly more
weight loss on average (11%; 22 pounds, p
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024